Cyclin-dependent kinase (CDK) 4/6 inhibitors in oncology.
- Published in:
- Forum of Clinical Oncology, 2019, v. 10, n. 2, p. 1, doi. 10.2478/fco-2019-0008
- By:
- Publication type:
- Article
Works matching IS 1792345X AND DT 2019 AND VI 10 AND IP 2
Results: 5
1
2
The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer.
- Published in:
- Forum of Clinical Oncology, 2019, v. 10, n. 2, p. 2, doi. 10.2478/fco-2019-0007
- By:
- Publication type:
- Article
3
Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia.
- Published in:
- Forum of Clinical Oncology, 2019, v. 10, n. 2, p. 15, doi. 10.2478/fco-2019-0005
- By:
- Publication type:
- Article
4
Assessing the potential role of neutrophil elastase as a prognostic indicator in oral squamous cell carcinoma.
- Published in:
- Forum of Clinical Oncology, 2019, v. 10, n. 2, p. 34, doi. 10.2478/fco-2019-0004
- By:
- Publication type:
- Article
5
Cancer Registry Report in Mansoura University Hospital, Egypt in 2015.
- Published in:
- Forum of Clinical Oncology, 2019, v. 10, n. 2, p. 26, doi. 10.2478/fco-2019-0003
- By:
- Publication type:
- Article